223 related articles for article (PubMed ID: 32276450)
1. Epstein-Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-immunotherapy.
Inoue H; Rai S; Tanaka H; Espinoza JL; Komori-Inoue M; Kakutani H; Minamoto S; Kumode T; Nakayama S; Taniguchi Y; Morita Y; Okuda T; Tatsumi Y; Ashida T; Matsumura I
Viruses; 2020 Apr; 12(4):. PubMed ID: 32276450
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
[TBL] [Abstract][Full Text] [Related]
3. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Kuriyama T; Kawano N; Yamashita K; Ueda A
J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
[TBL] [Abstract][Full Text] [Related]
5. Association of Epstein-Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with autoimmune diseases.
Fujimoto K; Hatanaka KC; Hatanaka Y; Kasahara I; Yamamoto S; Tsuji T; Nakata M; Takakuwa Y; Haseyama Y; Oyamada Y; Yonezumi M; Suzuki H; Sakai H; Noguchi H; Mori A; Nishihara H; Teshima T; Matsuno Y
Hematol Oncol; 2020 Dec; 38(5):799-807. PubMed ID: 32798315
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
Ru Y; Chen J; Wu D
Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
[TBL] [Abstract][Full Text] [Related]
7. Manifestations of fulminant CD8 T-cell post-transplant lymphoproliferative disorder following the administration of rituximab for lymphadenopathy with a high level of Epstein-Barr Virus (EBV) replication after allogeneic hematopoietic stem cell transplantation.
Tanaka T; Takizawa J; Miyakoshi S; Kozakai T; Fuse K; Shibasaki Y; Moriyama M; Ohshima K; Toba K; Furukawa T; Sone H; Masuko M
Intern Med; 2014; 53(18):2115-9. PubMed ID: 25224199
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
Nash RA; Dansey R; Storek J; Georges GE; Bowen JD; Holmberg LA; Kraft GH; Mayes MD; McDonagh KT; Chen CS; Dipersio J; Lemaistre CF; Pavletic S; Sullivan KM; Sunderhaus J; Furst DE; McSweeney PA
Biol Blood Marrow Transplant; 2003 Sep; 9(9):583-91. PubMed ID: 14506660
[TBL] [Abstract][Full Text] [Related]
9. CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.
Muramatsu H; Takahashi Y; Shimoyama Y; Doisaki S; Nishio N; Ito Y; Hama A; Shimada A; Yagasaki H; Ito M; Kojima S
Int J Hematol; 2011 Jun; 93(6):779-781. PubMed ID: 21559814
[TBL] [Abstract][Full Text] [Related]
10. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
Kinch A; Hallböök H; Arvidson J; Sällström K; Bondeson K; Pauksens K
Leuk Lymphoma; 2018 May; 59(5):1172-1179. PubMed ID: 28831836
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
[TBL] [Abstract][Full Text] [Related]
13. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
[TBL] [Abstract][Full Text] [Related]
14. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Analysis of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients].
Yan HM; Zheng XL; Zhu L; Ding L; Han DM; Liu J; Xue M; Li S; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1224-1229. PubMed ID: 35981389
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation.
Nozzoli C; Bartolozzi B; Guidi S; Orsi A; Vannucchi AM; Leoni F; Bosi A
Leuk Lymphoma; 2006 Jan; 47(1):167-9. PubMed ID: 16321845
[TBL] [Abstract][Full Text] [Related]
19. Utility of quantitative EBV DNA measurements in cerebrospinal fluid for diagnosis and monitoring of treatment of central nervous system EBV-associated post-transplant lymphoproliferative disorder after allogenic hematopoietic stem cell transplantation.
Bocian J; Januszkiewicz-Lewandowska D
Ann Transplant; 2014 May; 19():253-6. PubMed ID: 24866354
[TBL] [Abstract][Full Text] [Related]
20. Retransplantation after post transplant lymphoproliferative disorder: overcoming the obstacles!
Prasad P; Khullar D; Gupta N; Grover R; Chhabra G; Gandhi KR; Gupta S; Bagai S
CEN Case Rep; 2020 Aug; 9(3):200-203. PubMed ID: 32016786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
